PMID: 9420641Mar 1, 1995Paper

Long-term vasodilator treatment with flosequinan does not lead to hemodynamic tolerance or neurohormonal activation in severe heart failure

Journal of Cardiac Failure
G L BartelsD A Kruijssen

Abstract

Flosequinan is a balanced-type vasodilator with a prolonged mode of action due to an approximate 38-hour half-life of its active first metabolite, BTS 53554. As this may lead to tolerance and neurohormonal activation, the acute and long-term pharmacokinetic, hemodynamic, and neurohormonal profile of flosequinan was evaluated. On three consecutive days, 23 patients with heart failure (New York Heart Association classes II-IV), despite digitalis and diuretics, underwent invasive hemodynamic studies after receiving 100 mg oral flosequinan (day 1), placebo (day 2), and 100 mg flosequinan (day 3), followed by repeat invasive evaluation after long-term flosequinan (100 mg daily) for 17 +/- 2 weeks. On each study day, plasma flosequinan levels increased to 1.9 +/- 0.2 mg/L after 1 hour, but returned to baseline levels at 24 hours. In contrast, BTS 53554 increased progressively, reaching relatively high plateau levels (6 mg/L) during chronic therapy. First-dose flosequinan decreased the pulmonary wedge, right atrial pressure, and systemic resistance by 50, 60, and 22%, respectively, whereas the cardiac index was increased by 40%; these effects lasted for 48 hours. During long-term treatment, baseline values of the pulmonary wedge and r...Continue Reading

References

Apr 1, 1992·British Journal of Pharmacology·R W GristwoodP Berga
Dec 1, 1992·Journal of the American College of Cardiology·P G CaveroK Chatterjee
Mar 1, 1991·American Heart Journal·D B Yates
Mar 1, 1991·American Heart Journal·A J Cowley
Aug 1, 1991·The New England Journal of Medicine·UNKNOWN SOLVD InvestigatorsJay N Cohn
Sep 1, 1989·Journal of Cardiovascular Pharmacology·R FaloticoA J Tobia
Apr 1, 1989·British Heart Journal·J S ElbornD P Nicholls
Jul 16, 1988·BMJ : British Medical Journal·A J CowleyJ R Hampton
Apr 30, 1986·Clinica Chimica Acta; International Journal of Clinical Chemistry·J J HoffmannT J Benraad
Sep 27, 1984·The New England Journal of Medicine·J N CohnT Rector

❮ Previous
Next ❯

Citations

Jan 1, 1997·Fundamental & Clinical Pharmacology·R IsnardM Komajda

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.